Navigation Links
NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
Date:3/8/2013

LAWRENCE, Mass. and SEATTLE, March 8, 2013 /PRNewswire/ -- ADC 2013 Booth 417 -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it will host a special educational event  at the 33rd Annual Dialysis Conference (ADC) on Sunday, March 10, 2013 featuring  celebrity  and former NxStage System One™ user Stephen Furst . The event highlights System One dialyzor experiences in achieving work-life-dialysis balance with NxStage therapy. The events at ADC bring together renal care leaders and patients to discuss ways to improve the lives of and care for people with End Stage Renal Disease (ESRD).

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

The educational discussion with actor and director Stephen Furst , former NxStage user Joe Collins and current NxStage dialyzor Dr. George Williams , will focus on the health and lifestyle benefits of more frequent home hemodialysis with the NxStage System One. The session will also discuss work-life balance as a dialysis patient, with each participant sharing the role of the NxStage System One in providing the flexibility to continue working in their distinct and diverse fields, from the entertainment industry to law enforcement and healthcare. While 64 percent of the general population aged 18 to 55 works, only 21 percent of hemodialysis patients are able to work three months after therapy has begun. Yet clinical data and other reports suggest that more frequent home hemodialysis enables some motivated patients to return to the workforce or to further education.[i]

Stephen Furst 's successful career as an actor and director includes his most famous role as Flounder in the movie "Animal House." He has also appeared in television shows such as "St. Elsewhere" and "Babylon 5,"and provided character voices for animated films including "Little Mermaid II" and "Buzz Lightyear of Star Command." Joe Collins is a Massachusetts State Trooper who attributes his ability to continue working at this high-pressure, unpredictable job thanks to more frequent, at-home therapy with the System One, and receiving a kidney transplant in 2012. Dr. George Williams is a physician who was unable to work while receiving conventional, in-center hemodialysis therapy. After switching to more frequent home hemodialysis with the NxStage System One four years ago, he is now able to work again. The educational discussion among Furst, Collins and Williams will take place on Sunday, March 10 from 7:00 to 9:00 p.m. in Princessa & Foyer at the Grand Hyatt in Seattle during ADC.

"ADC is a tremendous event that enables the pioneers of renal care to come together, learn, share and work to improve the lives of people with kidney disease," says Jeffrey H. Burbank , Chief Executive Officer of NxStage. "We look forward to working with Stephen Furst , Joe Collins , Dr. George Williams and other patients and physicians to continue educating the renal community about the benefits of more frequent home hemodialysis. We are honored to play a critical role in helping dialysis patients lead healthier and more productive lives."

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). The System One also has a CE mark and has been cleared by Health Canada. Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients' homes and give patients the freedom to travel with their therapy. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road. 

About NxStage Medical

NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com

[i] Kraus MA, Cox CG, Summitt CL, et al. Work and travel in a large Short Daily Hemodialysis (SDHD) program. Abstract presented at American Society of Nephrology Annual Conference, 2007.

Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis. 2003;42(5):1020-1035.

Heidenheim PA, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis. 2003;42(S1)(S1):S36-S41.

Borg D, Weinstein D, NcNeil C, et al. Home dialysis: the future is now. Abstract presented at the Annual Dialysis Conference, 2008.

Lindsay RM. Daily hemodialysis: the time has come? Am J Kidney Dis. 2005;45(5):793-797.


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
3. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... March 29, 2017  Glenmark Pharmaceuticals, a global ... 301, an investigational fixed-dose combination of mometasone furoate ... twice-daily as a nasal spray being studied for ... are from a recently completed Phase 3 trial ... combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... submitted a letter to President Trump expressing their support for an independent Vaccine ... two Ph.D. scientists and one medical journalist, will hold a press conference at ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested ... Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The FASTBRACES ... orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system could ...
Breaking Medicine News(10 mins):